{"title":"艾滋病、肝炎和其他抗病毒药物临床药理学国际研讨会摘要。","authors":"","doi":"10.1111/bcp.16302","DOIUrl":null,"url":null,"abstract":"<p><b>23</b></p><p><b>Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling</b></p><p>Lu Hongzhou<sup>1</sup>, Meng Xianmin<sup>1</sup> and Qin Hong<sup>2</sup></p><p><sup>1</sup><i>The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology;</i> <sup>2</sup><i>Jiangsu Aidea Pharmaceutical Co., Ltd</i></p><p><b>Objectives:</b> Ainuovirine (ANV) is a newly developed next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) metabolized by CYP2C19. The primary objective of this study was to simulate and predict drug–drug interaction (DDI) between ainuovirine and rifampicin (RIF) combined with isoniazid (INH) using physiologically based pharmacokinetic (PBPK) modelling. Additionally, we aimed to recommend suitable dose adjustments for ANV for the treatment of people living with HIV (PLWH) coinfected with tuberculosis.</p><p><b>Methods:</b> A comprehensive whole-body PBPK model for DDI was developed using PK-SIM® (version 11.2, Open Systems Pharmacology, USA). This model was validated against phase 1 DDI study of ANV with RIF and reported clinical data for all drugs administered alone and ANV-RIF/ANV-INH dual- and triple-drug concomitantly. The model contained the potent induction and concentration-dependent inhibition mechanisms of RIF and INH on CYP2C19. The model was considered verified if the predicted pharmacokinetic values <i>vs</i>. observed were within 0.5–2-fold. Alternative dosing regimens for ANV were simulated to ensure that the C<sub>trough</sub> exceeded the clinical reference interval's lower limit of 153.04 ± 59.22 ng/mL, while the C<sub>max</sub> remained below the upper limit of 526.45 ± 143.52 ng/mL.</p><p><b>Results:</b> The PBPK model was successfully verified according to the criteria. Simulation of different dose adjustments predicted that a change in regimen to 225 mg ANV (75 + 150 mg, while 75 mg co-administered with RIF plus INH, 150 mg after 12 h) may alleviate the inhibition effect of INH on ANV C<sub>max</sub> and induction effect of RIF on ANV C<sub>trough</sub> at steady state, which were within the clinical reference intervals.</p><p><b>Conclusions:</b> The developed PBPK model characterized the opposite effect-mediated DDI between RIF and INH on ANV, accurately predicting a narrowed therapeutic window when 150 mg daily of ANV co-administered with RIF plus INH. A change in the ANV dosing regimen from 150 to 225 mg was predicted to mitigate the effect of the DDI on the C<sub>max</sub> and C<sub>trough</sub> of ANV, maintaining plasma concentration levels above the therapeutic threshold while not too high.</p><p><b>Keywords:</b> ainuovirine, drug–drug interactions, isoniazid, pharmacokinetics, rifampicin</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":"90 S1","pages":"17-18"},"PeriodicalIF":3.1000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.16302","citationCount":"0","resultStr":"{\"title\":\"Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling\",\"authors\":\"\",\"doi\":\"10.1111/bcp.16302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>23</b></p><p><b>Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling</b></p><p>Lu Hongzhou<sup>1</sup>, Meng Xianmin<sup>1</sup> and Qin Hong<sup>2</sup></p><p><sup>1</sup><i>The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology;</i> <sup>2</sup><i>Jiangsu Aidea Pharmaceutical Co., Ltd</i></p><p><b>Objectives:</b> Ainuovirine (ANV) is a newly developed next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) metabolized by CYP2C19. The primary objective of this study was to simulate and predict drug–drug interaction (DDI) between ainuovirine and rifampicin (RIF) combined with isoniazid (INH) using physiologically based pharmacokinetic (PBPK) modelling. Additionally, we aimed to recommend suitable dose adjustments for ANV for the treatment of people living with HIV (PLWH) coinfected with tuberculosis.</p><p><b>Methods:</b> A comprehensive whole-body PBPK model for DDI was developed using PK-SIM® (version 11.2, Open Systems Pharmacology, USA). This model was validated against phase 1 DDI study of ANV with RIF and reported clinical data for all drugs administered alone and ANV-RIF/ANV-INH dual- and triple-drug concomitantly. The model contained the potent induction and concentration-dependent inhibition mechanisms of RIF and INH on CYP2C19. The model was considered verified if the predicted pharmacokinetic values <i>vs</i>. observed were within 0.5–2-fold. Alternative dosing regimens for ANV were simulated to ensure that the C<sub>trough</sub> exceeded the clinical reference interval's lower limit of 153.04 ± 59.22 ng/mL, while the C<sub>max</sub> remained below the upper limit of 526.45 ± 143.52 ng/mL.</p><p><b>Results:</b> The PBPK model was successfully verified according to the criteria. Simulation of different dose adjustments predicted that a change in regimen to 225 mg ANV (75 + 150 mg, while 75 mg co-administered with RIF plus INH, 150 mg after 12 h) may alleviate the inhibition effect of INH on ANV C<sub>max</sub> and induction effect of RIF on ANV C<sub>trough</sub> at steady state, which were within the clinical reference intervals.</p><p><b>Conclusions:</b> The developed PBPK model characterized the opposite effect-mediated DDI between RIF and INH on ANV, accurately predicting a narrowed therapeutic window when 150 mg daily of ANV co-administered with RIF plus INH. A change in the ANV dosing regimen from 150 to 225 mg was predicted to mitigate the effect of the DDI on the C<sub>max</sub> and C<sub>trough</sub> of ANV, maintaining plasma concentration levels above the therapeutic threshold while not too high.</p><p><b>Keywords:</b> ainuovirine, drug–drug interactions, isoniazid, pharmacokinetics, rifampicin</p>\",\"PeriodicalId\":9251,\"journal\":{\"name\":\"British journal of clinical pharmacology\",\"volume\":\"90 S1\",\"pages\":\"17-18\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.16302\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of clinical pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bcp.16302\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcp.16302","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
23
Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Lu Hongzhou1, Meng Xianmin1 and Qin Hong2
1The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology;2Jiangsu Aidea Pharmaceutical Co., Ltd
Objectives: Ainuovirine (ANV) is a newly developed next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) metabolized by CYP2C19. The primary objective of this study was to simulate and predict drug–drug interaction (DDI) between ainuovirine and rifampicin (RIF) combined with isoniazid (INH) using physiologically based pharmacokinetic (PBPK) modelling. Additionally, we aimed to recommend suitable dose adjustments for ANV for the treatment of people living with HIV (PLWH) coinfected with tuberculosis.
Methods: A comprehensive whole-body PBPK model for DDI was developed using PK-SIM® (version 11.2, Open Systems Pharmacology, USA). This model was validated against phase 1 DDI study of ANV with RIF and reported clinical data for all drugs administered alone and ANV-RIF/ANV-INH dual- and triple-drug concomitantly. The model contained the potent induction and concentration-dependent inhibition mechanisms of RIF and INH on CYP2C19. The model was considered verified if the predicted pharmacokinetic values vs. observed were within 0.5–2-fold. Alternative dosing regimens for ANV were simulated to ensure that the Ctrough exceeded the clinical reference interval's lower limit of 153.04 ± 59.22 ng/mL, while the Cmax remained below the upper limit of 526.45 ± 143.52 ng/mL.
Results: The PBPK model was successfully verified according to the criteria. Simulation of different dose adjustments predicted that a change in regimen to 225 mg ANV (75 + 150 mg, while 75 mg co-administered with RIF plus INH, 150 mg after 12 h) may alleviate the inhibition effect of INH on ANV Cmax and induction effect of RIF on ANV Ctrough at steady state, which were within the clinical reference intervals.
Conclusions: The developed PBPK model characterized the opposite effect-mediated DDI between RIF and INH on ANV, accurately predicting a narrowed therapeutic window when 150 mg daily of ANV co-administered with RIF plus INH. A change in the ANV dosing regimen from 150 to 225 mg was predicted to mitigate the effect of the DDI on the Cmax and Ctrough of ANV, maintaining plasma concentration levels above the therapeutic threshold while not too high.
期刊介绍：
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
